Agonista de dopamina

Um agonista de dopamina ou agonista de receptor de dopamina é um composto que ativa receptores de dopamina. Agonistas de receptores de dopamina ativa vias de sinalização através de proteínas G triméricas e β-arrestinas, em última análise levando a mudanças em transcrição de genes.

Atualmente, para vários subtipos de agonistas de receptores de dopamina (D1, D2, D3) são conhecidos, que abordam diferencialmente essas vias de sinalização, são chamados agonistas tendenciosos [en].^[1]^[2]^[3]^[4]^[5]

Referências

↑ Möller D, Banerjee A, Uzuneser TC, Skultety M, Huth T, Plouffe B, Hübner H, Alzheimer C, Friedland K, Müller CP, Bouvier M, Gmeiner P (2017). «Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure». J. Med. Chem. 60 (7): 2908–2929. PMID 28248104. doi:10.1021/acs.jmedchem.6b01857
↑ Hübner H, Schellhorn T, Gienger M, Schaab C, Kaindl J, Leeb L, Clark T, Möller D, Gmeiner P (2016). «Structure-guided development of heterodimer-selective GPCR ligands». Nat Commun. 7. 12298 páginas. PMC 4963535 . PMID 27457610. doi:10.1038/ncomms12298
↑ Xu W, Wang X, Tocker AM, Huang P, Reith ME, Liu-Chen LY, Smith AB, Kortagere S (2017). «Functional Characterization of a Novel Series of Biased Signaling Dopamine D3 Receptor Agonists». ACS Chem Neurosci. 8 (3): 486–500. PMID 27801563. doi:10.1021/acschemneuro.6b00221
↑ Conroy, JL; Free, RB; Sibley, DR (15 de abril de 2015). «Identification of G protein-biased agonists that fail to recruit β-arrestin or promote internalization of the D1 dopamine receptor». ACS Chemical Neuroscience. 6 (4): 681–92. PMC 5234767 . PMID 25660762. doi:10.1021/acschemneuro.5b00020
↑ Park SM, Chen M, Schmerberg CM, Dulman RS, Rodriguiz RM, Caron MG, Jin J, Wetsel WC (2016). «Effects of β-Arrestin-Biased Dopamine D2 Receptor Ligands on Schizophrenia-Like Behavior in Hypoglutamatergic Mice». Neuropsychopharmacology. 41 (3): 704–15. PMC 4707817 . PMID 26129680. doi:10.1038/npp.2015.196

[pmid28248104-1] Möller D, Banerjee A, Uzuneser TC, Skultety M, Huth T, Plouffe B, Hübner H, Alzheimer C, Friedland K, Müller CP, Bouvier M, Gmeiner P (2017). «Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure». J. Med. Chem. 60 (7): 2908–2929. PMID 28248104. doi:10.1021/acs.jmedchem.6b01857

[pmid27457610-2] Hübner H, Schellhorn T, Gienger M, Schaab C, Kaindl J, Leeb L, Clark T, Möller D, Gmeiner P (2016). «Structure-guided development of heterodimer-selective GPCR ligands». Nat Commun. 7. 12298 páginas. PMC 4963535 . PMID 27457610. doi:10.1038/ncomms12298

[pmid27801563-3] Xu W, Wang X, Tocker AM, Huang P, Reith ME, Liu-Chen LY, Smith AB, Kortagere S (2017). «Functional Characterization of a Novel Series of Biased Signaling Dopamine D3 Receptor Agonists». ACS Chem Neurosci. 8 (3): 486–500. PMID 27801563. doi:10.1021/acschemneuro.6b00221

[pmid25660762-4] Conroy, JL; Free, RB; Sibley, DR (15 de abril de 2015). «Identification of G protein-biased agonists that fail to recruit β-arrestin or promote internalization of the D1 dopamine receptor». ACS Chemical Neuroscience. 6 (4): 681–92. PMC 5234767 . PMID 25660762. doi:10.1021/acschemneuro.5b00020

[pmid26129680-5] Park SM, Chen M, Schmerberg CM, Dulman RS, Rodriguiz RM, Caron MG, Jin J, Wetsel WC (2016). «Effects of β-Arrestin-Biased Dopamine D2 Receptor Ligands on Schizophrenia-Like Behavior in Hypoglutamatergic Mice». Neuropsychopharmacology. 41 (3): 704–15. PMC 4707817 . PMID 26129680. doi:10.1038/npp.2015.196

[1]

[2]

[3]

[4]

[5]